]. 78. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec. 12(6):734-40. [QxMD MEDLINE Link]. 79. Watchko JF. Common hematologic problems in the newborn nursery. Pediatr Clin North Am. 2015 Apr. 62 (2):509-24. [QxMD MEDLINE Link
cells. Because it is a blood product, it has risks of transmission of viral infections such as hepatitis C and may not be acceptable in some religious denomination. Hence 2 monoclonal anti-D antibodies derived from recombinant technology, BRAD-1 and BRAD-3, are being tested in clinical trials. A new novel polyclonal recombinant antibody, rozrolimupab has also been tested in phase I and II clinical
cells. Because it is a blood product, it has risks of transmission of viral infections such as hepatitis C and may not be acceptable in some religious denomination. Hence 2 monoclonal anti-D antibodies derived from recombinant technology, BRAD-1 and BRAD-3, are being tested in clinical trials. A new novel polyclonal recombinant antibody, rozrolimupab has also been tested in phase I and II clinical
]. 78. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec. 12(6):734-40. [QxMD MEDLINE Link]. 79. Watchko JF. Common hematologic problems in the newborn nursery. Pediatr Clin North Am. 2015 Apr. 62 (2):509-24. [QxMD MEDLINE Link
]. 78. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec. 12(6):734-40. [QxMD MEDLINE Link]. 79. Watchko JF. Common hematologic problems in the newborn nursery. Pediatr Clin North Am. 2015 Apr. 62 (2):509-24. [QxMD MEDLINE Link
the antibody nofetumomab to the radioisotope technetium-99m.[40] * Rozrolimupab is a polyclonal antibody. Broken down into rozro-lim-u-pab, its name shows the drug to be a human polyclonal antibody (-pab) acting on the immune system.[41]Convention from 2009 to 2017[edit] * Olaratumab is an antineoplastic. Its name is composed of the components olara-t-u-mab. This shows that the drug is a human monoclonal (INN) for Pharmaceutical Substances: Names for radicals & groups comprehensive list" (PDF). World Health Organization. 2002: 22. Archived from the original (PDF) on July 3, 2011. Retrieved 2010-12-24. {{cite journal}}: Cite journal requires |journal= (help) 41. ^ USAN Council. "Statement On A Nonproprietary Name Adopted By The Usan Council - Rozrolimupab" (PDF). American Medical Association